CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 32 enrolled
Drug / intervention
Ampion +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04880161
NCT04880161Phase 1Completed
CompareCT.gov

A Randomized, Double-Blinded, Placebo-Controlled Phase I Study to Evaluate the Safety and Efficacy of Ampion in Patients With Prolonged Respiratory Symptoms Due to COVID-19 (Long COVID)

Ampio Pharmaceuticals. Inc.·interventional·Posted May 10, 2021·Updated Sep 21, 2023

In Brief

A Phase 1 clinical trial evaluating Ampion and Placebo for Covid19. Completed, enrolled 32 participants across 1 site.

Detailed Summary

This is a phase I study to evaluate the safety and efficacy of inhaled Ampion on patients with prolonged respiratory symptoms due to COVID-19 (Long COVID).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCovid19
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
20222023202420252026
First PostedMay 10, 2021
Enrollment StartJul 26, 2021
Primary CompletionDec 22, 2021
Study CompletionFeb 21, 2022
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 5.1 years ago

Interventions

Ampionbiological

Inhaled Ampion

Placeboother

Inhaled Placebo